Veteran Healthcare Investor Farah Champsi to Join InterWest Partners
Veteran Healthcare Investor Farah Champsi to Join InterWest Partners May 2015
Menlo Park, CA – May 27, 2015 — InterWest Partners (www.interwest.com), a leading venture capital firm, announced today that veteran healthcare investor, Farah Champsi, will be joining InterWest’s Healthcare team as a Managing Director. Champsi will leverage her three decades of investment banking and venture investing expertise to seek new investment opportunities in the biotechnology sector and expand InterWest’s leadership in healthcare investing.
“Farah is a proven biotechnology investor with an impressive portfolio that has produced major gains throughout her fifteen years at Alta Partners. We are very proud to have her as part of the leadership of our investing team, alongside Gil Kliman and me, and she will be a valuable asset in our future fundraising efforts,” said Arnie Oronsky, Managing Director at InterWest.
Champsi is currently a Managing Director at Alta and serves on the boards of Allakos and Kite Pharma. She is also responsible for Alta's investments in Achaogen, Chimerix, Cytokinetics, Intarcia, Portola and Trevena, and will continue to manage her Alta portfolio during her transition to InterWest. Previously, she led Alta's investments in Agensys (acquired by Astellas), Esperion (acquired by Pfizer), Excaliard (acquired by Pfizer) and Orphan Medical (acquired by Jazz).
Prior to joining Alta in 2000, Champsi was Head of Global Life Sciences Investment Banking at Robertson Stephens & Company, where she focused on biotechnology and other life sciences companies. She joined Robertson Stephens in 1987, was elected a General Partner in 1992, and was responsible for building one of the most successful life sciences investment banking franchises on Wall Street during her thirteen-year tenure as an investment banker there. She has an M.B.A. from Stanford University and a B.A. in Economics from Smith College.
“Farah brings to us a unique depth and breadth of investing experience combined with a long tenure as a healthcare industry leader. This addition will enhance the InterWest Healthcare team and accelerate the forward momentum of our successful franchises in biotechnology, medical devices, and digital health,” said Gil Kliman, Managing Director at InterWest.
"InterWest has a longstanding reputation of excellence in venture investing and I am excited to join and contribute to their continued success,” said Champsi. “The healthcare industry, and particularly biotech, is undergoing unprecedented innovation and value creation. In addition, we have receptive capital markets and opportunities for exit through either acquisition or going public. It's a great time to be a venture investor in healthcare."
About InterWest Partners
For over thirty-six years, InterWest Partners has partnered with exceptional entrepreneurs to build winning healthcare and technology companies. The healthcare team has invested in 150 companies since 1979, completed 40 IPOs, and participated in 37 upside acquisitions. Some of the firm's past successful investments in healthcare include: AkaRx (acquired by Eisai), Amplimmune (acquired by AstraZeneca, AZN), ArthroCare (ARTC), Aspreva Pharmaceuticals (ASPV; acquired by Galenica group, GALN), CNS Therapeutics (acquired by Covidien, COV), Cor Therapeutics (CORR; acquired by Millennium Pharmaceuticals, MLNM), Corixa Pharmaceuticals (CRXA; acquired by GlaxoSmithKline, GSK), Coulter Pharmaceutical (CLTR; acquired by Corixa Pharmaceuticals, CRXA), Cubist Pharmaceuticals (CBST; acquired by Merck, MRK), Epicor Medical (acquired by St. Jude Medical, STJ), Epocrates (EPOC; acquired by AthenaHealth, ATHN), Inspire Pharmaceuticals (ISPH), IntraLase (ILSE; acquired by Advanced Medical Optics, EYE), Kai Pharmaceuticals (acquired by Amgen, AMGN), Labrys Biologics (acquired by Teva Pharmaceuticals, TEVA), LenSx Lasers (acquired by Alcon, ACL), Myogen (MYOG; acquired by Gilead, GILD), Nanostim (acquired by St. Jude Medical), NovaCardia (acquired by Merck, MRK), Signal Pharmaceuticals (acquired by Celgene, CELG), Spinal Dynamics (acquired by Medtronic, MDT), TheraSense (THER; acquired by Abbott Labs, ABT), Trius (TSRX; acquired by Cubist, CBST), and Ventritex (VNTX; acquired by St. Jude Medical, STJ).